EA202090776A1 - Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) - Google Patents
Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha)Info
- Publication number
- EA202090776A1 EA202090776A1 EA202090776A EA202090776A EA202090776A1 EA 202090776 A1 EA202090776 A1 EA 202090776A1 EA 202090776 A EA202090776 A EA 202090776A EA 202090776 A EA202090776 A EA 202090776A EA 202090776 A1 EA202090776 A1 EA 202090776A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fibroblast
- fapalpha
- visualizing
- activating protein
- protein alpha
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000001959 radiotherapy Methods 0.000 title 1
- 238000003384 imaging method Methods 0.000 abstract 2
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000003439 radiotherapeutic effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575607P | 2017-10-23 | 2017-10-23 | |
| PCT/US2018/057086 WO2019083990A2 (en) | 2017-10-23 | 2018-10-23 | IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090776A1 true EA202090776A1 (ru) | 2020-07-27 |
Family
ID=66247306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090776A EA202090776A1 (ru) | 2017-10-23 | 2018-10-23 | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US20200330624A1 (enExample) |
| EP (1) | EP3700580A4 (enExample) |
| JP (2) | JP2021500373A (enExample) |
| KR (2) | KR102764076B1 (enExample) |
| CN (2) | CN111511408A (enExample) |
| AU (2) | AU2018355222B2 (enExample) |
| BR (1) | BR112020008011A2 (enExample) |
| CA (1) | CA3088138A1 (enExample) |
| EA (1) | EA202090776A1 (enExample) |
| IL (1) | IL274088A (enExample) |
| MX (2) | MX2020004807A (enExample) |
| WO (1) | WO2019083990A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| SG11202005563YA (en) * | 2017-12-15 | 2020-07-29 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| MX2020008271A (es) * | 2018-02-06 | 2020-11-09 | Univ Heidelberg | Inhibidor de fap. |
| JP7161044B2 (ja) | 2018-10-17 | 2022-10-25 | パーデュー・リサーチ・ファウンデーション | 線維症における線維芽細胞活性化タンパク質（ｆａｐ）を標的とする撮像法および治療法 |
| WO2020132661A2 (en) | 2018-12-21 | 2020-06-25 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| EP3997104A1 (en) | 2019-07-08 | 2022-05-18 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| IL289675B1 (en) | 2019-07-08 | 2025-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a protein ligand for fibroblast activation and their use |
| CN114901315B (zh) * | 2019-09-17 | 2025-04-29 | 普渡研究基金会 | 癌症和其他纤维化和炎性疾病的成纤维细胞活化蛋白(fap)靶向的成像和治疗 |
| US20230100158A1 (en) * | 2020-01-31 | 2023-03-30 | Purdue Research Foundation | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
| PL3891138T3 (pl) | 2020-02-12 | 2022-05-02 | Philochem Ag | Białkowe ligandy aktywacji fibroblastów do zastosowań w celowanym dostarczaniu |
| WO2021224438A1 (en) | 2020-05-07 | 2021-11-11 | Institut Curie | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| WO2021234181A1 (en) * | 2020-05-22 | 2021-11-25 | Universität Heidelberg | Use of fap inhibitor in a method of diagnosis |
| CN112138175A (zh) * | 2020-09-01 | 2020-12-29 | 上海市质子重离子临床技术研发中心 | 一种放射性核素99mTc标记FAPI的化合物的制备方法 |
| CN114790194B (zh) * | 2020-12-21 | 2024-03-26 | 苏州药明博锐生物科技有限公司 | 成纤维细胞活化蛋白抑制剂 |
| EP4050018A1 (en) * | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| AU2022205523A1 (en) * | 2021-01-07 | 2023-07-13 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| JP7651785B2 (ja) * | 2021-02-10 | 2025-03-27 | 烟台藍納成生物技術股▲ふん▼有限公司 | 切断型エバンスブルー修飾線維芽細胞活性化タンパク質阻害剤及びその調製方法と応用 |
| CN114369084B (zh) * | 2021-02-10 | 2023-02-03 | 烟台蓝纳成生物技术有限公司 | 一种截短型伊文思蓝修饰的成纤维细胞活化蛋白抑制剂及其制备方法和应用 |
| KR20230145162A (ko) | 2021-02-12 | 2023-10-17 | 필로켐 아게 | 표적 전달 이용을 위한 2가 섬유모세포 활성화 단백질 리간드 |
| EP4043452A1 (en) | 2021-02-12 | 2022-08-17 | Philochem AG | Bivalent fibroblast activation protein ligands for targeted delivery applications |
| CN113105432B (zh) * | 2021-03-30 | 2022-03-04 | 上海交通大学医学院附属仁济医院 | 一种碳-11（11c）放射性药物及其制备方法和应用 |
| EP4313049A1 (en) * | 2021-04-02 | 2024-02-07 | The Johns Hopkins University | Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen |
| CN113277989B (zh) * | 2021-04-27 | 2022-05-31 | 中南大学湘雅医院 | 一种68Ga标记的分子探针、制备方法及其应用 |
| WO2022241506A1 (en) * | 2021-05-19 | 2022-11-24 | Ferronova Pty Ltd | Mapping nanoparticles |
| CN113527266A (zh) * | 2021-06-23 | 2021-10-22 | 上海健康医学院 | 一种靶向fap的双氧水响应的前药及其制备方法与应用 |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| EP4122499A1 (en) * | 2021-07-23 | 2023-01-25 | 3B Pharmaceuticals GmbH | Fibroblast activation protein inhibitors and use thereof |
| TW202320805A (zh) * | 2021-08-18 | 2023-06-01 | 美商杜夫特學院信託管理公司 | 用於pet造影之選擇性靶向纖維母細胞活化蛋白之放射性氟標誌試劑 |
| CN113880810B (zh) * | 2021-09-24 | 2023-02-28 | 厦门大学 | 一种核素标记的配合物及其制备方法和应用 |
| MX2024004077A (es) | 2021-10-04 | 2024-04-18 | Philochem Ag | Ligandos de proteina de activacion de fibroblastos radioetiquetados. |
| TW202317541A (zh) | 2021-10-28 | 2023-05-01 | 行政院原子能委員會核能研究所 | 一種靶向成纖維細胞活化蛋白之化合物或其鹽，其製備方法及其用途 |
| WO2023081301A1 (en) * | 2021-11-05 | 2023-05-11 | On Target Laboratories, LLC | Fibroblast activation protein targeted dyes their related uses |
| US20250177582A1 (en) | 2022-01-30 | 2025-06-05 | Philochem Ag | High-affinity ligands of fibroblast activation protein for targeted delivery applications |
| EP4483905A1 (en) * | 2022-02-22 | 2025-01-01 | Osaka University | Radiolabeled fap-alpha-affinity compound and use thereof |
| US20250263393A1 (en) * | 2022-04-21 | 2025-08-21 | Shanghai Sinotau Biotech. Co., Ltd | Fap inhibitors |
| WO2023222558A1 (en) | 2022-05-14 | 2023-11-23 | Zounek Alexis Nikolai | Precursor and theranostic radiotracer with improved tumor retention |
| CN115304582B (zh) * | 2022-07-20 | 2023-05-12 | 北京法伯新天医药科技有限公司 | FAP-α特异性肿瘤诊断显像剂 |
| IL318543A (en) * | 2022-07-28 | 2025-03-01 | Ratio Therapeutics Inc | Protein-targeted compositions for activating fibroblasts and methods for using them |
| CN115368342B (zh) * | 2022-08-24 | 2024-01-23 | 西南医科大学附属医院 | 成纤维细胞活性蛋白抑制剂、其放射性核素标记物及制备方法和应用 |
| CN119816493A (zh) | 2022-09-06 | 2025-04-11 | 菲罗化学股份公司 | 用于靶向递送应用的多价成纤维细胞激活蛋白配体 |
| EP4342890A1 (en) | 2022-09-21 | 2024-03-27 | Erasmus University Rotterdam Medical Center | Platform and scaffold for fap targeting agents |
| JP2025532104A (ja) * | 2022-09-23 | 2025-09-29 | ヌクリディウム アクチェンゲゼルシャフト | 高純度銅放射性医薬組成物ならびにその診断および治療用途 |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| CN117883585A (zh) * | 2022-10-14 | 2024-04-16 | 无锡诺宇医药科技有限公司 | 靶向成纤维细胞活化蛋白的药物及其应用 |
| EP4653451A1 (en) * | 2023-02-10 | 2025-11-26 | Chengdu New Radiomedicine Technology Co., Ltd. | Polypeptide compound and use thereof |
| CN120957982A (zh) * | 2023-05-08 | 2025-11-14 | 江苏恒瑞医药股份有限公司 | 靶向成纤维细胞活化蛋白的配体 |
| WO2025029608A1 (en) * | 2023-07-28 | 2025-02-06 | Ratio Therapeutics, Inc. | Fibroblast activation protein-targeted compositions and methods of use thereof |
| WO2025046043A1 (en) | 2023-08-31 | 2025-03-06 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
| WO2025063849A2 (en) | 2023-09-21 | 2025-03-27 | Erasmus University Medical Center Rotterdam | Dimeric fap targeting agents |
| WO2025125335A1 (en) | 2023-12-13 | 2025-06-19 | Radiovaxx Gmbh | Cytotoxic or radiopharmaceutical compound with sulfur fluoride exchange group |
| WO2025125621A1 (en) | 2023-12-14 | 2025-06-19 | Radiovaxx Gmbh | Cancer-associated protein-targeted strong or covalently binding precursor compounds and radiotracers |
| WO2025146433A1 (en) | 2024-01-05 | 2025-07-10 | Radiovaxx Gmbh | Precursor and theranostic radiotracer with prolonged tumor retention |
| CN118063689B (zh) * | 2024-01-26 | 2025-01-28 | 锐康九域(厦门)医药科技有限公司 | 成纤维细胞激活蛋白-α响应水解致电荷翻转的聚合物-药物偶联物及其制备方法和应用 |
| CN118271393B (zh) * | 2024-05-31 | 2024-09-03 | 中国药科大学 | 一种靶向fap的二聚化合物及其探针和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006125227A2 (en) * | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| CA2694266C (en) * | 2007-06-26 | 2016-06-14 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| DK3222615T3 (da) * | 2008-08-01 | 2022-06-20 | Univ Johns Hopkins | Psma-bindende stoffer og anvendelser deraf |
| CN102203061A (zh) * | 2008-09-25 | 2011-09-28 | 分子制药洞察公司 | 选择性seprase抑制剂 |
| WO2016149188A1 (en) * | 2015-03-13 | 2016-09-22 | The Johns Hopkins University | 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS |
| PL3964502T3 (pl) * | 2009-03-19 | 2024-10-28 | The Johns Hopkins University | Związki do kierunkowania w psma i ich zastosowania |
| US9346814B2 (en) * | 2012-01-17 | 2016-05-24 | Universiteit Antwerp | FAP inhibitors |
| US20150320892A1 (en) * | 2012-06-29 | 2015-11-12 | Ge Healthcare Limited | Imaging fibrosis |
| WO2014028057A1 (en) * | 2012-08-15 | 2014-02-20 | Visen Medical, Inc. | Prostate specific antigen agents and methods of using same for prostate cancer imaging |
| WO2015114166A2 (en) * | 2014-02-03 | 2015-08-06 | Philochem Ag | Targeted drug conjugates |
| WO2016065142A2 (en) * | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
| US10857246B2 (en) * | 2015-06-01 | 2020-12-08 | The Johns Hopkins University | Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| MX2020008271A (es) | 2018-02-06 | 2020-11-09 | Univ Heidelberg | Inhibidor de fap. |
-
2018
- 2018-10-23 WO PCT/US2018/057086 patent/WO2019083990A2/en not_active Ceased
- 2018-10-23 EA EA202090776A patent/EA202090776A1/ru unknown
- 2018-10-23 US US16/758,182 patent/US20200330624A1/en active Pending
- 2018-10-23 KR KR1020207013693A patent/KR102764076B1/ko active Active
- 2018-10-23 BR BR112020008011-0A patent/BR112020008011A2/pt unknown
- 2018-10-23 KR KR1020247035948A patent/KR20240162157A/ko active Pending
- 2018-10-23 MX MX2020004807A patent/MX2020004807A/es unknown
- 2018-10-23 EP EP18871298.8A patent/EP3700580A4/en active Pending
- 2018-10-23 CN CN201880083520.XA patent/CN111511408A/zh active Pending
- 2018-10-23 CN CN202310498227.2A patent/CN116617420A/zh active Pending
- 2018-10-23 AU AU2018355222A patent/AU2018355222B2/en active Active
- 2018-10-23 CA CA3088138A patent/CA3088138A1/en active Pending
- 2018-10-23 JP JP2020523010A patent/JP2021500373A/ja active Pending
-
2020
- 2020-04-20 IL IL274088A patent/IL274088A/en unknown
- 2020-07-13 MX MX2023013164A patent/MX2023013164A/es unknown
-
2023
- 2023-07-18 US US18/354,282 patent/US11938201B2/en active Active
-
2024
- 2024-02-23 US US18/585,905 patent/US12115233B2/en active Active
- 2024-05-14 JP JP2024078640A patent/JP2024109682A/ja active Pending
- 2024-05-16 AU AU2024203249A patent/AU2024203249A1/en active Pending
- 2024-12-20 US US18/990,863 patent/US20250186628A1/en active Pending
-
2025
- 2025-04-07 US US19/172,114 patent/US20250235565A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12115233B2 (en) | 2024-10-15 |
| KR20240162157A (ko) | 2024-11-14 |
| EP3700580A2 (en) | 2020-09-02 |
| US20200330624A1 (en) | 2020-10-22 |
| KR20200063230A (ko) | 2020-06-04 |
| US20240293584A1 (en) | 2024-09-05 |
| AU2024203249A1 (en) | 2024-06-06 |
| IL274088A (en) | 2020-06-30 |
| CN116617420A (zh) | 2023-08-22 |
| MX2023013164A (es) | 2023-11-23 |
| WO2019083990A3 (en) | 2019-06-13 |
| AU2018355222A1 (en) | 2020-04-30 |
| JP2021500373A (ja) | 2021-01-07 |
| MX2020004807A (es) | 2020-10-05 |
| US20250186628A1 (en) | 2025-06-12 |
| AU2018355222B2 (en) | 2024-10-03 |
| JP2024109682A (ja) | 2024-08-14 |
| KR102764076B1 (ko) | 2025-02-05 |
| WO2019083990A2 (en) | 2019-05-02 |
| CA3088138A1 (en) | 2019-05-02 |
| EP3700580A4 (en) | 2021-06-23 |
| BR112020008011A2 (pt) | 2020-10-27 |
| US11938201B2 (en) | 2024-03-26 |
| US20230364274A1 (en) | 2023-11-16 |
| CN111511408A (zh) | 2020-08-07 |
| US20250235565A1 (en) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090776A1 (ru) | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) | |
| IL280707A (en) | Diagnostic and therapeutic methods for the treatment of breast cancer | |
| MX2023015185A (es) | Degradadores de proteinas y usos de los mismos. | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| MX2019006072A (es) | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). | |
| MX2019011148A (es) | Metodos de tratamiento. | |
| MX390878B (es) | Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1). | |
| EA202091846A1 (ru) | Соединения с активностью, индуцирующей ферроптоз, и способы их применения | |
| PE20181156A1 (es) | Genes de ataxia de friedreich modificados y vectores para terapia genica | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| MX387283B (es) | Tratamiento del cancer con tg02. | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| MA40607B1 (fr) | Traitements médicaux à base d'anamoréline | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EA202192400A1 (ru) | Антитела против интегрина и их применение | |
| JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения |